ERBB2 and breast cancer: The addition of the anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab to chemotherapy improved time to disease progression, objective response rates and survival in patients with metastatic, HER2-positive breast cancer compared to chemotherapy alone (Slamon et al. 2001).